Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry
| Autor: | Esteban Daudén, Gregorio Carretero, Raquel Rivera, Carlos Ferrándiz, Mar Llamas-Velasco, Pablo de la Cueva, Isabel Belinchón, Francisco José Gómez-García, Enrique Herrera-Acosta, Diana Patricia Ruiz-Genao, Marta Ferrán-Farrés, Mercè Alsina, Ofelia Baniandrés-Rodríguez, José Luis Sánchez-Carazo, Antonio Sahuquillo-Torralba, Lourdes Rodriguez Fernández-Freire, Jaime Vilar-Alejo, Carmen García-Donoso, José Manuel Carrascosa, Enrique Herrera-Ceballos, José Luis López-Estebaranz, Rafael Botella-Estrada, Eva Segovia-Muñoz, Miguel Angel Descalzo, Ignacio García-Doval, Ferrán Ballescá, Fran J. Gómez-García, Rafael Jiménez, Marta Ferrán Farrés, Ofelia Baniandrés, Lula Nieto, Conrad Pujol Marco, Lourdes Rodríguez Fernández-Freire, Almudena Mateu Puchades, Ángeles Flórez Menéndez, Laura Salgado, Beatriz González Sixto, Noemí Eiris, Miguel Ángel Descalzo Gallego, Marina de Vega Martínez |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
safety
Adult Male medicine.medical_specialty Time Factors biologic agents prospective cohort long-term follow-up Dermatology immunosuppressive agents anti-inflammatory agents Cohort Studies 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Internal medicine Psoriasis Ustekinumab medicine Adalimumab Humans Registries Adverse effect Prospective cohort study Aged business.industry registries psoriasis/drug therapy anti-TNF Middle Aged medicine.disease Infliximab Biological Therapy Spain 030220 oncology & carcinogenesis pharmacovigilance adverse effects Secukinumab Female Apremilast business medicine.drug |
| Zdroj: | JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante instname |
| ISSN: | 1097-6787 0190-9622 |
| Popis: | Background: Registry studies broadly describing the safety of systemic drugs in psoriasis are needed. Objective: To describe the safety findings of the systemic drugs acitretin, adalimumab, apremilast, cyclosporine, etanercept, infliximab, methotrexate, secukinumab, and ustekinumab used for the treatment of moderate to severe psoriasis in patients included in the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry. Methods: The incidence rate ratio (IRR) and adjusted IRR (including propensity scores) of identified adverse events for each drug, using methotrexate as reference, were determined by means of a prospective cohort. Results: Our study included 2845 patients (8954 treatment cycles; 9642 patient-years). Ustekinumab and secukinumab had the lowest rate of adverse events for several of the system organ classes, with a statistically significant decreased rate ratio (IRR of = 5). Limitations: Observational study, drug allocation not randomized, depletion of susceptibles, and prescribed doses not registered. Conclusion: Our data provide comparative safety information in the real-life setting that could help clinicians selecting between available products. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect